CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

GC Biopharma signs Fabry disease drug licensing deal with BioMarin worth up to USD 237.5 million

By Public Technologies
  • GC Biopharma signed a USD 237.5 million licensing deal with BioMarin Pharmaceutical for Fabry disease treatment LA-GLA on Oct. 29, 2026.
  • The agreement includes USD 35 million upfront and USD 202.5 million in milestone payments tied to development, approval and commercialization.
  • BioMarin receives exclusive global licensing rights; Korean approval and commercialization rights remain with GC Biopharma and Hanmi Pharmaceutical.
  • Royalties will be payable based on annual net sales following commercialization.
  • LA-GLA, jointly developed with Hanmi Pharmaceutical, is undergoing Phase 1/2 clinical trials in South Korea and overseas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GC Biopharma Corp. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800005), on October 30, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk